Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14758666 | 1.00 | RIPK1 (0.55) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL5609841 | 0.90 | RIPK1 (0.53) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL1154790 | 0.83 | LMNA (0.58) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL11228716 | 0.83 | RIPK1 (0.53) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| Benzene SCHEMBL27821286 | 0.83 | LMNA (0.58) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL4416648 | 0.83 | LMNA (0.58) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL6689030 | 0.83 | LMNA (0.58) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL792175 | 0.80 | HRH1 (0.50) | LMNAHPGDHTR1AALDH1A1 | |
| SCHEMBL5185803 | 0.79 | RIPK1 (0.64) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL3081755 | 0.79 | RIPK1 (0.64) | RIPK1LMNAKDM4EL3MBTL1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000642-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | TAY THERAPEUTICS LTD (GB) | 2026-01-01 | — | — | US | disclosed |
| US-20250263370-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | Tay Therapeutics Limited (GB) | 2025-08-21 | — | — | US | disclosed |
| EP-4558224-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | Tay Therapeutics Limited (GB) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024018423-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | Tay Therapeutics Limited (GB) | 2024-01-25 | — | — | WO | disclosed |
| WO-2012138648-A1 | COMPOSITIONS AND METHODS FOR MODULATING LPA RECEPTORS | IRM LLC (BM) | 2012-10-11 | — | — | WO | disclosed |
| US-8268894-B2 | Compositions and methods for the treatment of infectious diseases | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-09-18 | — | — | US | disclosed |
| US-20110118307-A1 | Compositions and methods for the treatment of infectious diseases | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2011-05-19 | — | — | US | disclosed |
| US-7842729-B2 | Anti tubercular drug: compositions and methods | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-30 | — | — | US | disclosed |
| US-7456222-B2 | Anti tubercular drug: compositions and methods | SEQUELLA, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20060148904-A1 | Anti tubercular drug: compositions and methods | SEQUELLA, INC. | 2006-07-06 | — | — | US | disclosed |
| US-20060020041-A1 | Anti tubercular drug: compositions and methods | SEQUELLA, INC. | 2006-01-26 | — | — | US | disclosed |
| US-6951961-B2 | Methods of use and compositions for the diagnosis and treatment of infectious disease | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2005-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118307-A1 | Compositions and methods for the treatment of infectious diseases | TERT, C5, ELANE | RIPK1 3262/4885LMNA 940/4885KDM4E 2144/4885 |
| US-20260000642-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | BET1, BRD4, PHKB | RIPK1 797/4885LMNA 3175/4885KDM4E 947/4885 |
| US-20060148904-A1 | Anti tubercular drug: compositions and methods | C5, DERA, ELL | RIPK1 3444/4885LMNA 1085/4885KDM4E 1205/4885 |
| US-20250263370-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | BET1, PHKB, BRD4 | RIPK1 182/4885LMNA 4331/4885KDM4E 309/4885 |
| US-20060020041-A1 | Anti tubercular drug: compositions and methods | C5, DERA, ELL | RIPK1 3444/4885LMNA 1085/4885KDM4E 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.